These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

838 related items for PubMed ID: 28531826

  • 1. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L, Plana N, Pérez-Calahorra S, Ibarretxe D, Lamiquiz-Moneo I, Pedro-Botet J, Suárez-Tembra M, Valdivielso P, Ortega E, Civeira F, Dyslipidemia Registry of the Spanish Arteriosclerosis Society.
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [Abstract] [Full Text] [Related]

  • 2. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Vrablik M, Raslová K, Vohnout B, Blaha V, Satny M, Kyselak O, Vaclova M, Urbanek R, Maskova J, Soska V, Freiberger T.
    Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
    [Abstract] [Full Text] [Related]

  • 3. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    van Delden XM, Huijgen R, Wolmarans KH, Brice BC, Barron JK, Blom DJ, Marais AD.
    Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
    [Abstract] [Full Text] [Related]

  • 4. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ.
    JAMA Cardiol; 2017 Sep 01; 2(9):959-966. PubMed ID: 28768335
    [Abstract] [Full Text] [Related]

  • 5. PCSK9 inhibitors in clinical practice: Delivering on the promise?
    Stoekenbroek RM, Hartgers ML, Rutte R, de Wijer DD, Stroes ESG, Hovingh GK.
    Atherosclerosis; 2018 Mar 01; 270():205-210. PubMed ID: 29254691
    [Abstract] [Full Text] [Related]

  • 6. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN).
    Atheroscler Suppl; 2017 Nov 01; 30():44-49. PubMed ID: 29096860
    [Abstract] [Full Text] [Related]

  • 7. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
    Scicali R, Di Pino A, Urbano F, Ferrara V, Marchisello S, Di Mauro S, Scamporrino A, Filippello A, Rabuazzo AM, Purrello F, Piro S.
    Nutr Metab Cardiovasc Dis; 2021 Mar 10; 31(3):869-879. PubMed ID: 33549441
    [Abstract] [Full Text] [Related]

  • 8. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH, Santos RD.
    Prog Cardiovasc Dis; 2019 Mar 10; 62(5):414-422. PubMed ID: 31669498
    [Abstract] [Full Text] [Related]

  • 9. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ, Hovingh GK, Catapano AL.
    Atherosclerosis; 2018 Oct 10; 277():483-492. PubMed ID: 30270089
    [Abstract] [Full Text] [Related]

  • 10. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, Ballantyne CM.
    Circ Cardiovasc Qual Outcomes; 2018 May 10; 11(5):e004652. PubMed ID: 29748356
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K.
    JAMA; 2016 Aug 16; 316(7):743-53. PubMed ID: 27533159
    [Abstract] [Full Text] [Related]

  • 12. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
    Gencer B, Koskinas KC, Räber L, Karagiannis A, Nanchen D, Auer R, Carballo D, Carballo S, Klingenberg R, Heg D, Matter CM, Lüscher TF, Rodondi N, Mach F, Windecker S.
    J Am Heart Assoc; 2017 Nov 09; 6(11):. PubMed ID: 29122809
    [Abstract] [Full Text] [Related]

  • 13. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
    Rizos CV, Skoumas I, Rallidis L, Skalidis E, Tziomalos K, Garoufi A, Anagnostis P, Sfikas G, Kotsis V, Doumas M, Kolovou G, Lambadiari V, Dima I, Kiouri E, Zacharis E, Agapakis D, Attilakos A, Antza C, Vlachopoulos C, Liberopoulos EN.
    Int J Cardiol; 2021 Dec 15; 345():119-124. PubMed ID: 34687802
    [Abstract] [Full Text] [Related]

  • 14. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F, Dal Pino B, Bigazzi F, Ripoli A, Passino C, Gabutti A, Pasanisi EM, Petersen C, Valleggi A, Todiere G, Barison A, Giannoni A, Panchetti L, Becherini F, Pianelli M, Luciani R, Sampietro T.
    Eur J Prev Cardiol; 2017 Sep 15; 24(14):1528-1531. PubMed ID: 28555526
    [Abstract] [Full Text] [Related]

  • 15. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P, SAFEHEART Investigators.
    J Am Coll Cardiol; 2016 Mar 22; 67(11):1278-85. PubMed ID: 26988947
    [Abstract] [Full Text] [Related]

  • 16. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ, Shah P, Goldenberg N, Prince M, Lee K, Jetty V, Kumar A, Goldenberg M, Wang P.
    Lipids Health Dis; 2016 Mar 12; 15():55. PubMed ID: 26968977
    [Abstract] [Full Text] [Related]

  • 17. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S, Boccara F, Cariou B, Carrié A, Collet X, Farnier M, Ferrières J, Krempf M, Peretti N, Rabès JP, Varret M, Vimont A, Charrière S, Bruckert E, French FH Registry group.
    Atherosclerosis; 2018 Oct 12; 277():334-340. PubMed ID: 30270068
    [Abstract] [Full Text] [Related]

  • 18. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B, Bourane S, Tang L, Farnier M, Raal FJ, Lambert G.
    Arterioscler Thromb Vasc Biol; 2018 Mar 12; 38(3):592-598. PubMed ID: 29284604
    [Abstract] [Full Text] [Related]

  • 19. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience.
    Mandraffino G, Scicali R, Rodríguez-Carrio J, Savarino F, Mamone F, Scuruchi M, Cinquegrani M, Imbalzano E, Di Pino A, Piro S, Rabuazzo AM, Squadrito G, Purrello F, Saitta A.
    J Clin Lipidol; 2020 Mar 12; 14(2):231-240. PubMed ID: 32111581
    [Abstract] [Full Text] [Related]

  • 20. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Pasta A, Cremonini AL, Formisano E, Fresa R, Bertolini S, Pisciotta L.
    Atherosclerosis; 2020 Sep 12; 308():6-14. PubMed ID: 32771803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.